These two show up together constantly — same general research category, similar marketing claims, frequently discussed as if interchangeable. They’re not the same molecule and don’t work the same way. Here’s the actual comparison.
Want something built around your specific situation, not general reading? PeptideReport.ai turns a short guided intake into a free, personalized educational report you can actually bring to your doctor — and registering gets you The Peptide Bridge audiobook free, a $29.99 value, delivered to your inbox right away.
Get my free report + free book →| BPC-157 | TB-500 | |
|---|---|---|
| What it is | A synthetic peptide fragment derived from a protein found in human gastric juice. | A synthetic version of a fragment of thymosin beta-4, a protein involved in cell structure and movement. |
| Category | Healing & recovery research peptide | Healing & recovery research peptide |
| Proposed mechanism | Studied for effects on blood vessel formation (angiogenesis) and gut-lining protection in animal models. | Studied for its role in cell migration and actin regulation — the cellular "scaffolding" involved in tissue remodeling. |
| Evidence base | Almost entirely animal and in-vitro studies; originally researched for gastrointestinal protection, later studied for broader tissue effects in rodent models. | Primarily animal studies, plus research on the naturally-occurring parent protein (thymosin beta-4) in wound healing. |
| Regulatory status | Research-use-only in the US. | Research-use-only in the US. |
| Where people mix them up | Both are marketed for the same general use case (recovery/tissue repair), both are frequently discussed in the same forum threads, and both get referred to loosely as "healing peptides" without distinguishing their actual mechanisms. | |
The short version: they're marketed to the same audience for the same broad goal (recovery from injury or physical stress), and most vendor and forum content describes benefits in outcome terms ("supports healing") rather than mechanism terms, which makes two chemically distinct compounds sound like variations on the same thing. Once you look at mechanism instead of marketing copy, they're clearly different: one is a gastric-derived fragment studied mostly for angiogenesis and gut effects, the other is a thymosin-beta-4-derived fragment studied for cell migration. Different origin, different proposed pathway.
For both compounds, the honest summary is: promising mechanistic and animal-model findings, very limited to no controlled human trial data. That's a meaningfully different statement than "proven to help X in people," which is how both compounds are frequently described in marketing. Neither has completed the clinical trial process required for FDA approval for any indication.
Both compounds have their own entries on the compounds reference page with additional detail. For the category they both belong to, see Healing & Recovery on the categories page. For more comparisons, see the comparisons hub.
Reading about this by name is a starting point, not a plan. PeptideReport.ai turns general reading like this into a free, personalized report you can bring to a licensed physician — the person actually qualified to weigh these considerations against your health history.
Get your free report at PeptideReport.ai →
Free bonus: register today and The Peptide Bridge audiobook — a physician-authored, plain-English guide to peptide therapy, a $29.99 value — is yours free, delivered to your inbox right away.